RA260
Ultra-potent next-generation mitochondrial uncoupler — 3-10x more powerful than BAM15 with maintained safety profile
Clinical Research Score: 1/5 — A very new and obscure compound with essentially no published human or verifiable research available yet.
Categories: Weight Loss / Metabolic, Performance & Energy
What is RA260?
RA260 is being called the "supercharged BAM15" — and for good reason. It belongs to the same class of mitochondrial uncouplers but is estimated to be 3 to 10 times more potent. That means it achieves the same fat-burning effects at much lower doses, which is a significant advantage for both effectiveness and tolerability.
The way it works is elegantly simple: RA260 forces your cells to burn fat for heat rather than storing it as energy. Your mitochondria essentially become less efficient on purpose — they have to burn more fuel to do the same work, and the excess energy is released as heat. The result is a meaningfully higher metabolic rate without needing to exercise more or eat less. Importantly, like BAM15, it specifically targets stubborn white fat tissue while sparing lean muscle.
Beyond weight loss, RA260 is generating serious research interest for metabolic health conditions. It shows promise for clearing fatty liver (NAFLD) by forcing the liver to burn off its fat stores. It rapidly improves insulin sensitivity by clearing excess glucose and lipids from the bloodstream. And unlike extreme dieting, it doesn't cause muscle wasting — your body is revving the engine harder, not starving the cells. For anyone following the evolution of safe mitochondrial uncouplers, RA260 represents the most potent option yet with a safety profile that avoids the deadly risks of older compounds like DNP.
How RA260 works
RA260 works by the same fundamental mechanism as BAM15 — creating a controlled proton leak across the inner mitochondrial membrane — but with dramatically greater potency. In a normal cell, mitochondria build up a proton gradient and use it to efficiently produce ATP. RA260 partially short-circuits this gradient, forcing mitochondria to burn significantly more fuel (primarily fat) to maintain the same energy output. The excess energy dissipates as heat. What makes RA260 special is its selectivity: it acts specifically on the mitochondrial membrane, not the cell's outer membrane, which is why it maintains the safety ceiling that makes it fundamentally different from DNP. At the tissue level, RA260 preferentially targets white adipose tissue, driving fat cells to waste their stored energy as heat. This produces rapid fat loss, reduced liver fat accumulation, and improved insulin sensitivity — all while preserving muscle mass and keeping body temperature within safe limits.
Scientific overview
RA260 is an advanced mitochondrial protonophore uncoupler that dissipates the inner mitochondrial membrane proton gradient with significantly greater potency than BAM15 (approximately 3-10x in in vitro assays). Like BAM15, RA260 selectively targets the mitochondrial membrane rather than the plasma membrane, maintaining a wide therapeutic index and avoiding the dangerous hyperthermia associated with classical uncouplers such as DNP. Preclinical data demonstrate robust reductions in adiposity, hepatic steatosis, and insulin resistance at substantially lower doses than BAM15, with preservation of lean body mass and normothermia. RA260 preferentially drives energy expenditure in white adipose tissue, effectively converting caloric surplus into heat dissipation rather than lipid storage.
Dosing
- Starting dose: 1-2 mg per day
- Common dosage range: 1-5 mg per day
- Administration: Subcutaneous
- Half-life: ~4-8 hours
- Frequency: 1x daily